NasdaqGS:ERASBiotechs
Erasca (ERAS) Valuation Check After Sharp Pullback And Premium Price To Book Ratio
Stock performance snapshot and trigger context
Erasca (ERAS) has drawn attention after recent trading left the stock with a 1 day return of about 0.5% and a 7 day decline of roughly 0.5%, prompting a closer look at its clinical stage oncology profile.
See our latest analysis for Erasca.
The recent 1 day share price return of about negative 48% and 7 day share price return of roughly negative 54% sit against a much stronger year to date share price return of about 176% and a very large 1 year...